Cholera - Pipeline Review, H1 2016

Publisher Name :
Date: 24-Feb-2016
No. of pages: 57
Inquire Before Buying

Global Markets Direct's, ‘Cholera - Pipeline Review, H1 2016', provides an overview of the Cholera pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Cholera, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Cholera and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Cholera

  • The report reviews pipeline therapeutics for Cholera by companies and universities/research institutes based on information derived from company and industry-specific sources

  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

  • The report reviews key players involved Cholera therapeutics and enlists all their major and minor projects

  • The report assesses Cholera therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

  • The report summarizes all the dormant and discontinued pipeline projects

  • The report reviews latest news related to pipeline therapeutics for Cholera

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

  • Identify and understand important and diverse types of therapeutics under development for Cholera

  • Identify potential new clients or partners in the target demographic

  • Develop strategic initiatives by understanding the focus areas of leading companies

  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

  • Devise corrective measures for pipeline projects by understanding Cholera pipeline depth and focus of Indication therapeutics

  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Cholera - Pipeline Review, H1 2016

Table of Contents

Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Cholera Overview 7
Therapeutics Development 8
Pipeline Products for Cholera - Overview 8
Pipeline Products for Cholera - Comparative Analysis 9
Cholera - Therapeutics under Development by Companies 10
Cholera - Therapeutics under Investigation by Universities/Institutes 11
Cholera - Pipeline Products Glance 12
Late Stage Products 12
Clinical Stage Products 13
Early Stage Products 14
Cholera - Products under Development by Companies 15
Cholera - Products under Investigation by Universities/Institutes 16
Cholera - Companies Involved in Therapeutics Development 17
Akthelia Pharmaceuticals Limited 17
Beijing Minhai Biotechnology Co., Ltd 18
PaxVax, Inc. 19
Cholera - Therapeutics Assessment 20
Assessment by Monotherapy Products 20
Assessment by Target 21
Assessment by Mechanism of Action 23
Assessment by Route of Administration 25
Assessment by Molecule Type 27
Drug Profiles 29
AKT-10082 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
cholera (trivalent) vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
cholera [strain O1/El/Tor/Ogawa] vaccine - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
crofelemer DR - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
gram-negative bacterial infections vaccine - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
IMSUTMR-1501 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Peptide for Cholera and Guillain-Barre Syndrome - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
PXVX-0200 - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
Small Molecules for Bacterial Infections - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
Small Molecules to Inhibit Sialic Acid Permease for Gram Negative Bacterial Infections - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Synthetic Peptides to Disrupt Cell Wall for Bacterial and Fungal Infections - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Cholera - Recent Pipeline Updates 42
Cholera - Dormant Projects 46
Cholera - Discontinued Products 47
Cholera - Product Development Milestones 48
Featured News & Press Releases 48
Dec 16, 2015: U.S. Food and Drug Administration Accepts Biologics License Application for PaxVax's Single-Dose Oral Cholera Vaccine Vaxchora 48
Feb 03, 2015: Napo Files Brief on Appeal In Dispute With Salix 48
Dec 08, 2014: PaxVax Announces Primary Endpoints Met in Phase 3 Cholera Vaccine Trial 49
Sep 30, 2014: Specialty Vaccine Company PaxVax to Present at 13th Annual BIO Investor Forum 50
Jul 01, 2014: Specialty Vaccine Company PaxVax Announces Positive Efficacy Results for Phase 3 Cholera Challenge Study 50
May 27, 2014: Specialty Vaccine Company PaxVax to Present at the Jefferies 2014 Global Healthcare Conference 51
Jan 09, 2014: PaxVax Announces Positive Interim Results for Phase 3 Cholera Challenge Study; Clinical Trial Program to Proceed as Planned 52
Sep 06, 2013: PaxVax Initiates Phase 3 Clinical Trial Challenge Studies for Single-Dose Oral Cholera Vaccine 53
Nov 14, 2012: PaxVax Presents Phase I Clinical Trial Results Of Single-dose Cholera Vaccine At 2012 ASTMH Annual Meeting 54
Mar 19, 2012: FDA Accepts PaxVax's IND for Single-Dose Oral Cholera Vaccine 55
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57

List of Tables

Number of Products under Development for Cholera, H1 2016 8
Number of Products under Development for Cholera - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Development, H1 2016 14
Products under Development by Companies, H1 2016 15
Products under Investigation by Universities/Institutes, H1 2016 16
Cholera - Pipeline by Akthelia Pharmaceuticals Limited, H1 2016 17
Cholera - Pipeline by Beijing Minhai Biotechnology Co., Ltd, H1 2016 18
Cholera - Pipeline by PaxVax, Inc., H1 2016 19
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Stage and Target, H1 2016 22
Number of Products by Stage and Mechanism of Action, H1 2016 24
Number of Products by Stage and Route of Administration, H1 2016 26
Number of Products by Stage and Molecule Type, H1 2016 28
Cholera Therapeutics - Recent Pipeline Updates, H1 2016 42
Cholera - Dormant Projects, H1 2016 46
Cholera - Discontinued Products, H1 2016 47

List of Figures

Number of Products under Development for Cholera, H1 2016 8
Number of Products under Development for Cholera - Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Late Stage Development, H1 2016 12
Comparative Analysis by Clinical Stage Development, H1 2016 13
Comparative Analysis by Early Stage Products, H1 2016 14
Assessment by Monotherapy Products, H1 2016 20
Number of Products by Targets, H1 2016 21
Number of Products by Stage and Targets, H1 2016 21
Number of Products by Mechanism of Actions, H1 2016 23
Number of Products by Stage and Mechanism of Actions, H1 2016 23
Number of Products by Routes of Administration, H1 2016 25
Number of Products by Stage and Routes of Administration, H1 2016 25
Number of Products by Molecule Types, H1 2016 27
Number of Products by Stage and Molecule Types, H1 2016 27
  • Global and United States Clostridium Difficile Treatment Market Research by Company, Type & Application 2013-2025
    Published: 20-Oct-2018        Price: US 2000 Onwards        Pages: 111
    Summary Market Segment as follows: By Type - Narrow Spectrum Antibiotics - Broad Spectrum Antibiotics By Application - Hospitals - Clinics - Others By Company - Actelion Pharmaceuticals - Merck - Pfizer - Summit Therapeutics - Astellas Pharma - CRESTOVO - Da Volterra - Immuron - MGB Biopharma - Novartis - Otsuka Pharmaceutical ......
  • Global Biologic Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 19-Oct-2018        Price: US 3480 Onwards        Pages: 136
    Biologic therapeutics drugs are genetically engineered proteins derived from human genetic material. They contain sugars, proteins, nucleic acids, or complex combinations of these substances, or may be living entities such as cells and tissues. In addition, biologics drugs are derived from natural sources such as animals, humans, and microorganisms that are further utilized to make therapeutic products such as vaccines, blood components, and recombinant therapeutic proteins. Scope......
  • Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 56
    Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Inclusion Body Myositis (IBM) - Pipeline Review, H2 2018, provides an overview of the Inclusion Body Myositis (IBM) (Musculoskeletal Disorders) pipeline landscape. Inclusion Body Myositis (IBM) is one of the inflammatory myopathies that involve inflammation of the muscles or associated tissues, such as th......
  • Kidney Transplant Rejection - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 175
    Kidney Transplant Rejection - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Transplant Rejection - Pipeline Review, H2 2018, provides an overview of the Kidney Transplant Rejection (Immunology) pipeline landscape. Kidney transplantation is a therapy performed to replace a diseased kidney with a healthy kidney from another person. Risk factors associated with transplantation ......
  • Peanut Allergy - Pipeline Review, H2 2018
    Published: 16-Oct-2018        Price: US 2000 Onwards        Pages: 117
    Peanut Allergy - Pipeline Review, H2 2018 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peanut Allergy - Pipeline Review, H2 2018, provides an overview of the Peanut Allergy (Immunology) pipeline landscape. Peanut allergy is common, especially in children. An allergic response to peanuts usually occurs within minutes after exposure, and symptoms range from mild to severe. Peanut allergy signs and symptoms ......
  • Global and United States Virus Like Particles Market Research by Company, Type & Application 2013-2025
    Published: 14-Oct-2018        Price: US 2000 Onwards        Pages: 117
    Summary Market Segment as follows: By Type - Adeno-Associated Virus - HIV - Hepatitis B Virus - Hepatitis C Virus - Others By Application - Vaccines - Mycoviruses - Virus Research - Therapeutic and Imaging Agents - Others By Company - GlaxoSmithKline - Merck - Novavax - Takeda - Medicago - MedImmune - TechnoVax ......
  • Global Enzyme Replacement Therapy Market Size, Status and Forecast 2018-2025
    Published: 09-Oct-2018        Price: US 3900 Onwards        Pages: 91
    This report focuses on the global Enzyme Replacement Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Enzyme Replacement Therapy development in United States, Europe and China. Enzyme replacement therapy (ERT) is a medical treatment which replaces an enzyme that is deficient or absent in the body. Usually, this is done by giving the patient an intravenous (IV) infusion of a solution containing the enzyme.......
  • Global Infantile Spasms Therapeutics Market Insights, Forecast to 2025
    Published: 09-Oct-2018        Price: US 3900 Onwards        Pages: 119
    This report studies the global market size of Infantile Spasms Therapeutics in key regions like North America, Europe, Asia Pacific, Central & South America and Middle East & Africa, focuses on the consumption of Infantile Spasms Therapeutics in these regions. This research report categorizes the global Infantile Spasms Therapeutics market by players/brands, region, type and application. This report also studies the global market status, competition landscape, market share, growth rate, f......
  • Global Gout Therapeutics Market 2018 by Manufacturers, Countries, Type and Application, Forecast to 2023
    Published: 09-Oct-2018        Price: US 3480 Onwards        Pages: 135
    Gout is a physical conditions that affects the patient's ability to move, often also termed as unwalkable disease, and it has been around for centuries. Scope of the Report: This report studies the Gout Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Gout Therapeutics market by product type and applications/en......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs